Display options
Cite
Krcek R, Matschke V, Theis V, et al. Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells. Front Oncol. 2017;7:182doi: 10.3389/fonc.2017.00182.
Krcek, R., Matschke, V., Theis, V., Adamietz, I. A., Bühler, H., & Theiss, C. (2017). Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells. Frontiers in oncology, 7182. https://doi.org/10.3389/fonc.2017.00182
Krcek, Reinhardt, et al. "Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells." Frontiers in oncology vol. 7 (2017): 182. doi: https://doi.org/10.3389/fonc.2017.00182
Krcek R, Matschke V, Theis V, Adamietz IA, Bühler H, Theiss C. Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells. Front Oncol. 2017 Aug 22;7:182. doi: 10.3389/fonc.2017.00182. eCollection 2017. PMID: 28879167; PMCID: PMC5572260.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2017 Aug 22;7:182. doi: 10.3389/fonc.2017.00182. eCollection 2017.

Vascular Endothelial Growth Factor, Irradiation, and Axitinib Have Diverse Effects on Motility and Proliferation of Glioblastoma Multiforme Cells.

Frontiers in oncology

Reinhardt Krcek, Veronika Matschke, Verena Theis, Irenäus Anton Adamietz, Helmut Bühler, Carsten Theiss

Affiliations

  1. Department of Cytology, Institute of Anatomy, Ruhr-University Bochum, Bochum, Germany.
  2. Department of Radiotherapy and Radio-Oncology, University Medical Centre Marien Hospital, Ruhr-University Bochum, Herne, Germany.
  3. Institute for Molecular Oncology, Radio-Biology and Experimental Radiotherapy, University Medical Centre Marien Hospital, Ruhr-University Bochum, Herne, Germany.

PMID: 28879167 PMCID: PMC5572260 DOI: 10.3389/fonc.2017.00182

Abstract

Glioblastoma multiforme (GBM) is the most common primary brain tumor. It is highly aggressive with an unfavorable prognosis for the patients despite therapies including surgery, irradiation, and chemotherapy. One important characteristic of highly vascularized GBM is the strong expression of vascular endothelial growth factor (VEGF). VEGF has become a new target in the treatment of GBM, and targeted therapies such as the VEGF-receptor blocker axitinib are in clinical trials. Most studies focus on VEGF-induced angiogenesis, but only very few investigations analyze autocrine or paracrine effects of VEGF on the tumor cells. In this study, we examined the impact of VEGF, irradiation, and axitinib on cell proliferation and cell motility in human GBM cell lines U-251 and U-373. VEGF receptor 2 was shown to be expressed within both cell lines by using PCR and immunochemistry. Moreover, we performed 24-h videography to analyze motility, and a viability assay for cell proliferation. We observed increasing effects of VEGF and irradiation on cell motility in both cell lines, as well as strong inhibiting effects on cellular motility by VEGF-receptor blockade using axitinib. Moreover, axitinib diminished irradiation induced accelerating effects. While VEGF stimulation or irradiation did not affect cell proliferation, axitinib significantly decreased cell proliferation in both cell lines. Therefore, the impairment of VEGF signaling might have a crucial role in the treatment of GBM.

Keywords: axitinib; cell motility; cell proliferation; glioma; irradiation; vascular endothelial growth factor; videography

References

  1. Cell Cycle. 2008 Aug 15;7(16):2553-61 - PubMed
  2. Chin J Cancer. 2014 Jan;33(1):32-9 - PubMed
  3. Neurol Med Chir (Tokyo). 2009 Apr;49(4):146-50; discussion 150-1 - PubMed
  4. PLoS One. 2013;8(3):e57188 - PubMed
  5. Cancer Sci. 2009 Nov;100(11):2085-92 - PubMed
  6. Radiat Oncol. 2012 Feb 22;7:25 - PubMed
  7. Cancer Res. 2012 Mar 1;72(5):1103-15 - PubMed
  8. Cancer Lett. 2002 Nov 28;185(2):153-61 - PubMed
  9. J Neurooncol. 2005 Sep;74(2):99-103 - PubMed
  10. Oncogene. 2004 Jan 15;23(2):434-45 - PubMed
  11. N Engl J Med. 2004 Jun 3;350(23 ):2335-42 - PubMed
  12. J Neurooncol. 2004 Mar-Apr;67(1-2):9-18 - PubMed
  13. Anticancer Res. 2015 Apr;35(4):1977-83 - PubMed
  14. Oncotarget. 2017 Jan 10;8(2):3380-3395 - PubMed
  15. Am J Pathol. 2004 May;164(5):1531-5 - PubMed
  16. Mol Cell Biol. 1995 Feb;15(2):954-63 - PubMed
  17. Neurosurgery. 1996 Aug;39(2):235-50; discussion 250-2 - PubMed
  18. N Engl J Med. 2014 Feb 20;370(8):709-22 - PubMed
  19. Genes Dev. 1995 Aug 1;9(15):1909-21 - PubMed
  20. Cancer Lett. 2011 Oct 28;309(2):145-50 - PubMed
  21. ScientificWorldJournal. 2013;2013:417413 - PubMed
  22. Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3749-54 - PubMed
  23. J Biol Chem. 1997 Jun 13;272(24):15442-51 - PubMed
  24. Endocr Rev. 1997 Feb;18(1):4-25 - PubMed
  25. Oncogene. 1997 Oct;15(18):2169-77 - PubMed
  26. Glia. 2012 May;60(6):936-47 - PubMed
  27. BMC Biochem. 2002 Dec 31;3:32 - PubMed
  28. Cancer Res. 1997 Oct 15;57(20):4593-9 - PubMed
  29. J Biol Chem. 2012 Jul 13;287(29):24821-31 - PubMed
  30. Nat Med. 2003 Jun;9(6):669-76 - PubMed
  31. J Biol Chem. 1998 May 22;273(21):13313-6 - PubMed
  32. Onco Targets Ther. 2013 Apr 15;6:371-89 - PubMed
  33. Strahlenther Onkol. 2017 Feb 14;:null - PubMed
  34. Radiother Oncol. 2002 Sep;64(3):259-73 - PubMed
  35. Science. 1983 Feb 25;219(4587):983-5 - PubMed
  36. Clin Cancer Res. 2009 Jul 15;15(14):4589-99 - PubMed
  37. J Neurooncol. 2003 May;62(3):297-303 - PubMed
  38. Cancer Res. 1999 Jul 15;59(14):3374-8 - PubMed
  39. Cell Transplant. 2011;20(1):121-5 - PubMed
  40. Cancer Res. 2001 Mar 15;61(6):2413-9 - PubMed
  41. Nature. 2004 Nov 18;432(7015):396-401 - PubMed
  42. Pediatr Blood Cancer. 2014 Sep;61(9):1603-9 - PubMed
  43. Science. 1989 Dec 8;246(4935):1306-9 - PubMed
  44. Nature. 1992 Oct 29;359(6398):845-8 - PubMed
  45. J Neurooncol. 1999;45(2):117-25 - PubMed
  46. Cancer Metastasis Rev. 2007 Jun;26(2):281-90 - PubMed
  47. J Biol Chem. 2000 Apr 7;275(14):10661-72 - PubMed
  48. Biochem Biophys Res Commun. 1993 Jan 15;190(1):140-7 - PubMed
  49. Carcinogenesis. 2014 Feb;35(2):383-95 - PubMed
  50. Lancet Oncol. 2013 Dec;14(13):1287-94 - PubMed
  51. Nat Cell Biol. 2000 May;2(5):249-56 - PubMed
  52. Microvasc Res. 2009 Mar;77(2):96-103 - PubMed
  53. Target Oncol. 2009 Dec;4(4):297-305 - PubMed
  54. Oncogene. 2001 May 31;20(25):3266-80 - PubMed
  55. Endocrinology. 2011 May;152(5):1745-51 - PubMed
  56. Arch Biochem Biophys. 2010 Oct 15;502(2):89-95 - PubMed
  57. EMBO J. 2001 Jun 1;20(11):2768-78 - PubMed
  58. Cancer Res. 2011 Apr 1;71(7):2675-85 - PubMed
  59. Clin Chem. 2007 Aug;53(8):1433-9 - PubMed
  60. Expert Opin Investig Drugs. 2009 Aug;18(8):1061-83 - PubMed
  61. Cancer Lett. 2012 May 28;318(2):221-5 - PubMed
  62. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed
  63. Neurosurgery. 2008 Apr;62(4):753-64; discussion 264-6 - PubMed
  64. J Atheroscler Thromb. 2006 Jun;13(3):130-5 - PubMed
  65. J Immunol. 2000 Feb 1;164(3):1169-74 - PubMed
  66. PLoS One. 2014 Jun 12;9(6):e99198 - PubMed
  67. J Neurooncol. 2015 Jan;121(1):91-100 - PubMed
  68. Cancer J. 2002 Jan-Feb;8(1):47-54 - PubMed

Publication Types